Becker's Healthcare November 16, 2023
Paige Twenter

The FDA and CDC are working to deploy more Beyfortus doses as its maker underestimated demand for the first respiratory syncytial virus drug approved for children.

On Nov. 16, the CDC said it released 77,000 Beyfortus (nirsevimab-alip) intramuscular injection solutions, which are being sent to physicians and hospitals through commercial channels and the CDC’s Vaccines for Children Program.

The nation’s RSV rate doubled from about 5% to 10% in one month, and children’s hospitals are feeling the strain. In Texas, the emergency department at Fort Worth Cook Children’s is seeing 500 patients a day with RSV and other respiratory viruses.

The fill rate of antibiotics for bacterial infections associated with RSV increased from 1.04% to 1.42%...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
Vaccines And AI
'Nobody knew exactly what to do': Five years on, what scientific lessons were learned during COVID?
World Tuberculosis Day 2025: the end of TB is possible
Did people experiencing homelessness have worse in-hospital outcomes from COVID-19 than housed people?
Measles cases surpass 2024 total: 3 notes

Share This Article